



CUBIC HEALTH INC.

*measure. understand. manage.*

**NOTICE OF COMPLIANCE FOR GENERIC LOSEC RE-INSTATED**

**TORONTO, June 3<sup>rd</sup>, 2005** – Following a May 18<sup>th</sup> Federal Court of Appeal decision to revoke Apotex Inc.'s license for their generic version of Losec®, the Notice of Compliance (NOC) for Apo-Omeprazole® capsules has been reinstated and they are once again available to pharmacies and patients across Canada. The Court of Appeal has stayed the order revoking the NOC pending a hearing on Apotex's Application for Leave to Appeal to the Supreme Court of Canada.

This dispute between the makers of Losec®, AstraZeneca Canada Inc., and Apotex has been one of technical interpretation of the Patent Regulations, and not in any way related to the safety and efficacy of Apo-Omeprazole® capsules. Apotex steadfastly maintains that their product is a safe and effective generic alternative.